A Chart Review to Evaluate the Safety and Efficacy of MeRT on Subjects With ASD

Sponsor
Wave Neuroscience (Industry)
Overall Status
Completed
CT.gov ID
NCT02758496
Collaborator
(none)
141
1
12
11.8

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).

Condition or Disease Intervention/Treatment Phase
  • Other: MeRT Efficacy Chart Review

Detailed Description

This is a retrospective chart review of 200 consecutive charts of subjects ages 2-20 years old seen at the Brain Treatment Center between 2010 and 2015. The review is designed to evaluate the safety and efficacy of Magnetic Electroencephalogram/Electrocardiogram(EEG/ECG)-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).

Study Design

Study Type:
Observational
Actual Enrollment :
141 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
A Chart Review to Evaluate the Safety and Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on Subjects With Autism Spectrum Disorder (ASD)
Study Start Date :
Apr 1, 2016
Actual Primary Completion Date :
Apr 1, 2017
Actual Study Completion Date :
Apr 1, 2017

Arms and Interventions

Arm Intervention/Treatment
ASD Subjects

Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.

Other: MeRT Efficacy Chart Review
There will be not intervention. This is a chart review.

Healthy Controls

Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group

Other: MeRT Efficacy Chart Review
There will be not intervention. This is a chart review.

Outcome Measures

Primary Outcome Measures

  1. Childhood Autism Rating Scale (CARS) [Baseline through study completion, an average of 36 months]

    Symptom reduction in ASD will be measured using the reduction in the CARS between two time points: Baseline (BL) CARS and Final CARS Evaluation.

Secondary Outcome Measures

  1. Electrophysiological [Baseline through study completion, an average of 36 months]

    Changes in quantitative electroencephalogram (qEEG), will be measured with emphasis on the overall changes between two timepoints: BL EEG and Final EEG.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 20 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Must have completed a baseline EEG at the Brain Treatment Center (BTC)

  2. Age between 2 and 20 years old at initial visit

  3. Must have a diagnosis of ASD according to the prevailing standard at that time (i.e., Diagnostic and Statistical Manual-IV (DSM-IV)) (ASD Group only)

  4. Must have received Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) for more than (5) sessions (ASD Group only)

Exclusion Criteria:
  1. Clinically significant abnormality or clinically significant unstable medical condition during treatment that in the Investigator's judgment may have may limited interpretation of the results.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brain Treatment Center Newport Beach California United States 92660

Sponsors and Collaborators

  • Wave Neuroscience

Investigators

  • Principal Investigator: Keun-Young Kim, MD, Brain Treatment Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Wave Neuroscience
ClinicalTrials.gov Identifier:
NCT02758496
Other Study ID Numbers:
  • MeRT-016
First Posted:
May 2, 2016
Last Update Posted:
May 9, 2017
Last Verified:
May 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Wave Neuroscience
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 9, 2017